News | Webinars | Publications | Conferences | Upcoming Events |
-
November 22, 2022
Why the TAAR1 agonist ulotaront holds promise for schizophrenia -
November 10, 2022
A novel phenotypic approach to CNS drug discovery -
October 24, 2022
4 next-gen CNS drug development trends -
October 12, 2022
Why Psychogenics and Emyria are collaborating to examine MDMA-inspired compounds -
October 11, 2022
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics -
September 22, 2022
Emyria starts program with neuroscience drug discovery CRO -
September 22, 2022
Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More -
September 21, 2022
Emyria teams with CRO PsychoGenics for MDMA-like drug development -
August 24, 2022
Overcoming mental health’s drug development challenges with AI -
August 22, 2022
PsychoGenics – Phenotypic Drug Discovery and Preclinical CRO -
August 17, 2022
Industrializing behavioral testing to redefine neuropsychiatric drug discovery -
August 15, 2022
We need a new Prozac: The demand for brain drug innovation -
August 14, 2022
Mental Health Champions: Why & How Dr. Emer Leahy of PsychoGenics Is Helping To Champion Mental Wellness -
August 5, 2022
The CNS drug development drum beat is getting louder -
June 29, 2022
PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities -
March 15, 2022
GBR Connect Series – Interview with Emer Leahy, PsychoGenics -
January 25, 2022
PsychoGenics’ High Data Security Standards Are Certified by The NIH -
December 14, 2021
PsychoGenics Appoints Dr. Stephen Morairty as Vice President, Translational Neuroscience and Jean-Sebastien Valois as Vice President, Engineering and AI Development -
October 11, 2021
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence -
September 25, 2020
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives -
September 16, 2020
PsychoGenics Drug Discovery Featured in Nature Biopharma Dealmakers -
July 28, 2020
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration -
November 6, 2019
PsychoGenics Awarded NIH HEAL Initiative Contract for Preclinical Screening Platform for Pain (PSPP) -
November 4, 2019
PsychoGenics Appoints Mark A. Varney, PhD as Chief Scientific Officer -
October 30, 2019
PsychoGenics Announces Milestones Associated with Sunovion’s Advancing Pipeline -
September 27, 2019
Sunovion and PsychoGenics Initiate DIAMOND Phase 3 Clinical Studies for SEP-363856 in the Treatment of Adults and Adolescents with Schizophrenia -
May 10, 2019
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia -
December 13, 2018
Sunovion and PsychoGenics Announce Positive Results from Pivotal Phase 2 Study of Novel Investigational Agent SEP-363856 for the Treatment of Schizophrenia -
March 15, 2018
PsychoGenics Obtains License to the TgF344-AD Rat Model of Alzheimer’s Disease -
December 4, 2017
Blue Oak & PsychoGenics Announce a Drug Discovery Partnership -
June 12, 2017
PsychoGenics Achieves a Milestone in Drug Discovery Collaboration with Sunovion -
April 4, 2016
PsychoGenics Drug Discovery Collaboration with Sunovion Achieves a Milestone -
January 27, 2016
PsychoGenics Obtains a License to the Line – 41 Mouse Model of Alzheimer’s Disease -
January 19, 2016
PsychoGenics Expands its Drug Discovery Service Capabilities -
January 12, 2016
PsychoGenics and the Alzheimer’s Drug Discovery Foundation Announce a Risk-Sharing Partnership for Preclinical Studies -
September 14, 2015
PsychoGenics Extends its Drug Discovery Collaboration with Sunovion -
August 11, 2015
PsychoGenics Obtains a License to Another Transgenic Mouse Model of α-Synucleinopathies -
March 15, 2015
PsychoGenics Obtains a License to α-synuclein Transgenic Mouse Models of Parkinson´s disease -
March 2, 2015
Resilience and PsychoGenics Announce a Drug Discovery Partnership -
January 27, 2015
PsychoGenics Achieves Another Milestone in Drug Discovery Collaboration with Sunovion -
January 21, 2015
PsychoGenics Obtains a License to the McGill-R-Thy1-APP Rat Model of Alzheimer’s Disease -
June 9, 2014
PsychoGenics Receives License to the Cntnap2 Knockout Mouse Model from the Weizmann Institute -
May 12, 2014
PsychoGenics Achieves Another Milestone in its Drug Discovery Collaboration with Sunovion -
April 22, 2014
PsychoGenics and Roche Expand Their Drug Discovery Partnership -
January 31, 2014
PsychoGenics Obtains a Non-Exclusive License to the rTg4510 Tauopathy Mouse Model -
August 21, 2013
PsychoGenics Obtains an Exclusive License to the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease -
June 17, 2013
PsychoGenics and Sunovion Pharmaceuticals Inc. Expand their Drug Discovery Partnership -
November 5, 2012
PsychoGenics Achieves Substantial Milestone in its Drug Discovery Collaboration with Sunovion -
July 16, 2012
Afraxis and PsychoGenics Form Alliance to Offer Afraxis’ ESP Technology for Drug Discovery -
June 12, 2012
PsychoGenics Inc. Announces Positive Efficacy Data in Levodopa Induced Dyskinesia in Parkinson’s Patients. -
February 8, 2012
PsychoGenics Expands its In Vivo Capabilities with the Addition of Preclinical Magnetic Resonance Imaging Technology Services in Partnership with Ekam Imaging. -
November 16, 2011
PsychoGenics Achieves Milestone in its Discovery Collaboration with Roche -
May 25, 2011
PsychoGenics and Evotec Enter into a Strategic Alliance to Provide Integrated CNS Drug Discovery Solutions -
February 14, 2011
PsychoGenics Expands its In Vivo Testing Capabilities with the Addition of Novel Neurogenesis Techniques in Partnership with KineMed Inc. -
February 18, 2010
PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr. -
August 30, 2009
PsychoGenics and AstraZeneca Enter Agreement to Identify New Treatments for Central Nervous System Disorders -
August 10, 2009
PsychoGenics Appoints David A. Lowe, as Chief Scientific Officer and Executive Vice President of Research and Development -
August 25, 2008
PsychoGenics Appoints John McCall, Ph.D. as Newest Member to its Scientific Advisory Board (SAB) -
June 2, 2008
PsychoGenics Announces Positive Phase-IIa for its First-in-Class Partial 5-HT1A – 5-HT1B Receptor Agonist in ADHD -
May 28, 2008
PsychoGenics Appoints Bavani Shankar, as Vice President, Corporate Development -
May 27, 2008
PsychoGenics and Roche Enter Agreement to Identify New Treatments for Neuropsychiatric Disorders -
March 4, 2008
PsychoGenics and Dainippon Sumitomo Pharma Sign Drug Discovery Agreement -
January 31, 2008
PsychoGenics Expands Drug Discovery Relationship With Eli Lilly and Company -
November 7, 2007
PsychoGenics Announces Drug Discovery Agreement with Cephalon -
April 13, 2007
Translational Research Forum to Explore Philanthropy and Drug Development At 2007 BIO International Convention. -
January 30, 2007
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals -
January 1, 2007
PsychoGenics, together with the Ewing Marion Kauffman Foundation, sponsors the Translational Research Forum at the BIO 2007 International Convention. -
December 19, 2006
PsychoGenics Announces Drug Discovery and Development Agreement with Eli Lilly and Company; Companies Will Work Together to Identify New Treatments for Neuropsychiatric Disorders -
October 4, 2006
PsychoGenics Appoints Rusiko Bourtchouladze, Ph.D. as Vice President, Cognition and Discovery Research -
September 22, 2006
PsychoGenics Expands Huntington Disease Research Collaboration with High Q Foundation and CHDI -
April 10, 2006
PsychoGenics and Sosei Partner to Identify New CNS Therapies -
February 24, 2006
PsychoGenics and SMA Foundation Extend Research Agreement -
July 6, 2005
PsychoGenics to provide testing services in the R6/2 Mouse Model for Huntington Disease -
November 15, 2004
PsychoGenics Names Paul McGonigle Chief Scientific Officer, and Jeff Schneider Chief Informatics Officer -
August 28, 2002
PsychoGenics Obtains Funding For Their High Throughput CNS Drug Discovery Platform -
June 11, 2002
Mark Hofer Esq. Joins PsychoGenics as General Counsel